Ionis Pharmaceuticals
PUBLIC
STATUS
701-800
EMPLOYEES
IONS
STOCK SYMBOL
15
INVESTMENTS
$61.69
SHARE PRICE
(As of Wednesday Closing)
Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline treats a wide variety of diseases, with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis sold rights to its first product, Kynamro, to Kastle Therapeutics after lackluster commercial success, but with partner Biogen brought its second drug, Spinraza for spinal muscular atrophy, to market. ATTR amyloidosis drug Tegsedi (inotersen) was approved in 2018 and cardiology drug Waylivra was approved in Europe in 2019.
Website
Formerly Known As
Isis Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 2855 Gazelle Court
- Carlsbad, CA 92010
- United States
+1 (760) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Ionis Pharmaceuticals’s full profile, request a free trial.
Ionis Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $48.27 - $86.58 | $8.68B | $62.91 | $3.13 | 985K | 141M |
Ionis Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 7,020,358 | 6,246,340 | 5,953,756 | 5,595,181 |
| Revenue | 821,033 | 599,674 | 514,179 | 372,776 |
| EBITDA | 181,575 | (18,839) | 36,338 | (9,638) |
| Net Income | 429,806 | 273,741 | 346 | (60,400) |
| Total Assets | 2,894,989 | 2,667,784 | 1,322,774 | 912,467 |
| Total Debt | 674,327 | 646,720 | 607,477 | 589,105 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ionis Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Ionis Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookIonis Pharmaceuticals Competitors (43)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 00000000 | 00.000 |
| 000000 | Formerly VC-backed | Cambridge, MA | 0000 | 000.00 | 00000000000 | 000.00 |
| 000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 0000 | |
| 0000000-00000 0000 | Corporation | New York, NY | 00000 | 00000 | 000000000 | 00000 |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
Ionis Pharmaceuticals Investments & Acquisitions (15)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 10-Nov-2017 | 000000000 | Biotechnology | 00000 00000 00.0 | |
| 0000000 00000 0000 | 06-Sep-2017 | 00000 00000 00 | 00.00 | Diagnostic Equipment | 0. 00000 00000000 00 |
| 00000000 | 01-Oct-2016 | 000000000000000000 | 00000 | Biotechnology | 00000 00000 00.0 |
| 0000000 0000000000 | 04-Oct-2012 | 000 | 0000 | Drug Discovery | 0. 00000 00000000 00 |
| Altair Therapeutics | 12-Nov-2009 | Early Stage VC | 0000 | Pharmaceuticals |
Ionis Pharmaceuticals Exits (5)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 00000000000 | 12-Nov-2009 | 00000 00000 00 | 0000 | Completed |
|
| 000000 00000000000 | 18-Dec-2007 | 00000 00000 00 | Completed |
|
|
| 000000000 00000000 | 16-Nov-2007 | 00000 00000 00 | 000.00 | Completed |
|
| 0000000 0000000000 | 15-Mar-2004 | 00000 00000 00 | 0000 | Completed |
|
| Protogene Laboratories | 01-Jan-1999 | Early Stage VC | 0000 | Completed |
|
Ionis Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Ionis Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookIonis Pharmaceuticals Executive Team (10)
2 Former Executives
You’re viewing 5 of 10 executives. Get the full list »Ionis Pharmaceuticals Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 0. 00000 00000000 00 | Ionis Pharmaceuticals | Board Member & Strategic Advisor | 000 0000 | |
| 00000 00000 00.0 | Ionis Pharmaceuticals | Chief Operating Officer & Board Member | 000 0000 | |
| 000000000 0000 00 | Self | Board Member | 000 0000 | |
| 0000 000000 | Self | Board Member | 000 0000 | |
| 000000 00000 000 | Ionis Pharmaceuticals | Board Member | 000 0000 |